InVitria's Recombinant Albumin-DX eliminates safety concerns, stabilizes sensitive biomarkers and enhances diagnostic performance by improving specificity.
Fort Collins, CO (PRWEB) April 2, 2009 -- Addressing significant product safety and consistency issues in the human diagnostics market, InVitria has announced the commercial launch of two protease-free recombinant albumin products. InVitria's Recombinant Albumin-DX and Recombinant Albumin-DX (Lipid-Free) perform better in diagnostics applications than both bovine serum albumin (BSA) and plasma-derived human serum albumin (pHSA).
The advantages of Recombinant Albumin-DX include:
- Reduce non-specific binding and improve specificity;
- Improved consistency due to recombinant manufacturing;
- Improved stabilization of sensitive proteins and biomarkers; and
- Reduce occupational safety risk and regulatory burden of handling human or animal blood products.
Customer testing has shown that Recombinant Albumin-DX (Lipid-Free) increased biomarker activity to levels twice as high as the current commercial alternative. In addition, stability over time was significantly improved with Recombinant Albumin-DX (Lipid-Free). Tests have also shown the bioequivalence of the Recombinant Albumin-DX to native human serum albumin (HSA).
"InVitria is committed to developing high performance, regulatory friendly products for the diagnostics market and our Recombinant Albumin-DX and DX Lipid-Free products deliver on this promise," said the company's President and CEO Scott Deeter. "Recombinant Album-DX and DX Lipid-Free provide the specificity, stability and consistency that diagnostic customers seek."
To receive a Recombinant Albumin-DX or DX Lipid-Free product materials packet, please contact InVitria's customer service specialists at 1-800-916-8311 or by e-mail at info@InVitria.com.
About InVitria
InVitria develops, manufactures and markets a portfolio of cell culture and diagnostic reagents. These products are used in cell culture, biopharmaceutical formulation, stem cell & regenerative medicine, medical devices and diagnostics.
Learn more about InVitria's products at http://www.invitria.com [Diagnostics__title__InVitria
###
Read the full story at http://www.prweb.com/releases/diagnostics/InVitria/prweb2291484.htm.
'/>"/>
| Source: PRWeb Copyright©2009 Vocus, Inc. All rights reserved |
Related medicine news :
1. InVitria to Present at WilBio's International Cell Engineering Meeting
2. InVitria to Showcase its Innovative Cell Culture Components at American Society of Cell Biology Annual Meeting
3. InVitria to Launch "BE FREE" Promotion at TERMIS '08 in San Diego
4. InVitria's Cellastim Delivers Superior Results in CHO Cell Culture
5. InVitria's Cell Culture Media Components Showcased at WilBio's 2008 Cell Engineering Meeting
6. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
7. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
8. UHW Announces: Antelope Valley Hospital Caregivers and Board Vote to Ratify First Union Contract With SEIU UHW-West
9. HEI, Inc. Announces Sale of RFID Division Assets
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
11. Mettler-Toledo International Inc. Announces Webcast of Presentation at Thomas Weisel Partners 2007 Healthcare Conference
| Copyright © 2003-2012 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |